Abstract
Clinical trial enrichment is the targeted recruitment of prospective individual patients with defined clinical characteristics who are likely to benefit from newly developed or repurposed drugs. This process is central to the success of clinical trials together with patient management and regulatory compliance. A main challenge in clinical trial enrichment lies in the recognition of a priori clinical parameters and information that informs drug efficacy or toxicity, particularly when intended for a broader unseen population. Although Artificial Intelligence (AI) approaches, especially large language models (LLMs), have been employed in many aspects of clinical trials, to our knowledge, there is no AI method that has been developed which offers a prospective prediction and assesses the extent to which a given therapeutic intervention benefits an unseen population. Here, we offer an outlook on how to build Artificial Clinic Intelligence (ACI), a generative AI (GAI)-powered modeling platform for modeling clinical trial enrichment. ACI generates synthetic patient data and models clinical trial enrichment to inform clinicians on key clinical parameters that are enriched in prospective patients prior to accrual.